Last updated: 2026-09-09 12:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lakewood-Amedex Biotherapeutics Inc. (LABT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,05, with a market capitalization of $4,46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,66 to $98,20. This page covers its latest market performance, valuation, price trends and company information.
$4,46M | |
$2,30 | |
$98,20 | |
$1,66 | |
$2,18 | |
3,04M | |
1,78M | |
-- | |
$98,20 | |
$1,66 | |
-- | |
-- |
Lakewood-Amedex Biotherapeutics Inc. (LABT) is trading at $2,05 in pre-market trading as of 2026-09-09 12:43:00, down 6,19% ($0,14) from the previous close of $2,18
Pre-market trading shows how investors are pricing LABT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Lakewood-Amedex Biotherapeutics Inc. (LABT) moved from $2,30 to $2,05, representing a decline of 11,09% ($0,25).
The stock traded between $1,86 and $2,86 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,67 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,4%
LABT is currently trading at $2,05, placing it 0,4% of the way from its 52-week low of $1,66 to its 52-week high of $98,20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.